Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 5

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

,

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

EP. 1: An Overview of HR+, HER2- Metastatic Breast Cancer
EP. 2: Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
EP. 3: The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
EP. 4: Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
Now Viewing
EP. 5: CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
EP. 6: The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
EP. 7: The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
EP. 8: Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
EP. 9: Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

Related Content:

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast CancerOncLive News Network®Breast Cancer
Key Considerations When Ordering Biomarker Testing
Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer
Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care